Recently, enhanced mitochondrial dynamics have emerged as a common vulnerability of drug-resistant and aggressive cancer cells, and the mitochondrial fission mediator DRP1 has been repeatedly suggested as a potential therapeutic target (9, 11, 17, 18, 27). This evidence concerns the gene DNM1L and cancer.